Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kiyoharu Shirakawa is active.

Publication


Featured researches published by Kiyoharu Shirakawa.


Tetrahedron Letters | 1981

The configuration and conformation of the arabinose moiety in platycodins, saponins isolated from platycodon grandiflorum, and mi-saponins from madhuca longifolia based on carbon-13 and hydrogen-1 nmr spectroscopic evidence: The total structures of the saponins

Hiroshi Ishii; Isao Kitagawa; Kazuhiro Matsushita; Kiyoharu Shirakawa; Kazuo Tori; Takehiko Tozyo; Masayuki Yoshikawa; Yohko Yoshimura

Abstract 13 C and 1 H FT NMR spectroscopy provided confirmatory evidence for the anomeric α configuration and the predominance of the 1 C 4 conformation of the L-arabinopyranose moiety in all saponins hitherto isolated from the title plants.


Journal of Cerebral Blood Flow and Metabolism | 1995

The Neuroprotective Effect of the Novel Noncompetitive NMDA Antagonist, FR115427 in Focal Cerebral Ischemia in Rats

Kiyotaka Katsuta; Hajime Nakanishi; Kiyoharu Shirakawa; Keizo Yoshida; Kiyoshi Takagi; Akira Tamura

The present study was carried out to compare the neuroprotective effect of the novel noncompetitive NMDA antagonist, FR115427, with that of (+)MK-801 in rat focal cerebral ischemia. Focal cerebral ischemia was produced by permanent occlusion of the left middle cerebral artery (MCA). Drugs were administered intraperitoneally immediately after ischemia and once a day for 6 successive days. FR115427 (10 mg/kg, i.p.) significantly improved neurologic deficit at 1 day after ischemia and reduced total infarct volume (54%) at 7 days after ischemia. Although FR115427 (10 mg/kg, s.c.) produced neuronal vacuolization similar to (+)MK-801, FR115427 did not produce adverse effects such as a loss of body weight, mortality, and hypothermia, in contrast to (+)MK-801. These results suggest that FR115427 may be useful in the treatment of stroke.


European Journal of Pharmacology | 1993

Neurochemical and electrophysiological studies on FR115427, a novel non-competitive NMDA receptor antagonist

Joseph P. Hodgkiss; Helen J. Sherriffs; David A. Cottrell; Kiyoharu Shirakawa; John S. Kelly; Atsushi Kuno; Mitsuru Ohkubo; Steven P. Butcher; Henry J. Olverman

The pharmacological profile of FR115427 has been examined using ligand binding and electrophysiological techniques. Binding of [3H]dizocilpine in the presence of L-glutamate was inhibited by the (+) isomers of dizocilpine and FR115427. The corresponding (-) isomers were less active, and stereoselectivity was particularly marked in the case of FR115427. In contrast to dizocilpine, the affinity of FR115427 for [3H]dizocilpine binding sites was little affected by addition of either L-glutamate and/or glycine. In a cortical wedge preparation, FR115427 inhibited N-methyl-D-aspartate (NMDA)-induced responses in a non-competitive, use-dependent manner. Intracellularly recorded excitatory synaptic responses in hippocampal neurones were only partially inhibited by FR115427 thereby confirming a selective effect on the NMDA-mediated component of neuronal excitation induced by the endogenous neurotransmitter. The data suggest that FR115427 is a non-competitive, use-dependent NMDA receptor antagonist with more pronounced stereoselectivity and less marked use dependence than dizocilpine.


Chemical & Pharmaceutical Bulletin | 1996

Studies on cerebral protective agents. IX. Synthesis of novel 1,2,3,4-tetrahydroisoquinolines as N-methyl-D-aspartate antagonists.

Mitsuru Ohkubo; Atsushi Kuno; Kiyotaka Katsuta; Yoshiko Ueda; Kiyoharu Shirakawa; Hajime Nakanishi; Isao Nakanishi; Takayoshi Kinoshita; Hisashi Takasugi


Japanese Journal of Pharmacology | 1994

Protective Effect of FR115427 against Ischemic Hippocampal Damage in Gerbils.

Hajime Nakanishi; Kiyotaka Katsuta; Takako Koide; Yoshiko Ueda; Kiyoharu Shirakawa; Keizo Yoshida


Chemical & Pharmaceutical Bulletin | 1981

Chemical transformation of uronic acids leading to aminocyclitols. III. Syntheses of aminocyclitols and aminocyclitol-oligoglycosides from uronic acids and glucuronide-saponins by means of electrolytic decarboxylation.

Isao Kitagawa; Masayuki Yoshikawa; Toshiyuki Kamigauchi; Kiyoharu Shirakawa; Yoshiharu Ikeda


Chemical & Pharmaceutical Bulletin | 1979

Effects of crude drugs on congestive edema.

Johji Yamahara; Yuko Takagi; Tokunosuke Sawada; Hajime Fujimura; Kiyoharu Shirakawa; Masayuki Yoshikawa; Isao Kitagawa


Chemical & Pharmaceutical Bulletin | 1996

Studies on Cerebral Protective Agents. X. Synthesis and Evaluation of Anticonvulsant Activities for Novel 4, 5, 6, 7-Tetrahydrothieno[3, 2-c]pyridines and Related Compounds

Mitsuru Ohkubo; Atsuchi Kuno; Kiyotaka Katsuya; Yoshiko Ueda; Kiyoharu Shirakawa; Hajime Nakanishi; Takayoshi Kinoshita; Hisashi Takasugi


Japanese Journal of Pharmacology | 1988

Effects of acetyl-L-carnitine on the brain lipofuscin content and emotional behavior in aged rats

Yoshiro Kohjimoto; Toshikazu Ogawa; Masahiro Matsumoto; Kiyoharu Shirakawa; Tomoyuki Kuwaki; Hiroshi Yasuda; Koretake Anami; Toshiyuki Fujii; Hisashi Satoh; Takaharu Ono


Japanese Journal of Pharmacology | 1987

Comparative Study of Tiapride and Neuroleptics with Anti-Dopamine Activity on Convulsive Seizure in Mice

Hisashi Satoh; Hajime Nakanishi; Kiyoharu Shirakawa; Yoshiro Kohjimoto; Tomoyuki Kuwaki; Takaharu Ono; Fumio Shibayama

Collaboration


Dive into the Kiyoharu Shirakawa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge